89Zr

You have access
Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm

Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776
You have access
⁸⁹Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression
Kyung-Ho Jung, Jin Won Park, Jin Hee Lee, Seung Hwan Moon, Young Seok Cho and Kyung-Han Lee

Journal of Nuclear Medicine May 10, 2021, 62 (5) 656-664; DOI: https://doi.org/10.2967/jnumed.120.250720
You have access
Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44
Philipp Diebolder, Cedric Mpoy, Jalen Scott, Truc T. Huynh, Ryan Fields, Dirk Spitzer, Nilantha Bandara and Buck E. Rogers

Journal of Nuclear Medicine January 1, 2021, 62 (1) 137-143; DOI: https://doi.org/10.2967/jnumed.120.249557
You have access
Light-Induced Radiosynthesis of ⁸⁹Zr-DFO-Azepin-Onartuzumab for Imaging the Hepatocyte Growth Factor Receptor
Simon Klingler, Rachael Fay and Jason P. Holland

Journal of Nuclear Medicine July 1, 2020, 61 (7) 1072-1078; DOI: https://doi.org/10.2967/jnumed.119.237180
You have access
⁸⁹Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo
Yvonne W.S. Jauw, Joseph A. O’Donoghue, Josée M. Zijlstra, Otto S. Hoekstra, C. Willemien Menke-van der Houven van Oordt, Franck Morschhauser, Jorge A. Carrasquillo, Sonja Zweegman, Neeta Pandit-Taskar, Adriaan A. Lammertsma, Guus. A.M.S. van Dongen, Ronald Boellaard, Wolfgang A. Weber and Marc C. Huisman

Journal of Nuclear Medicine December 1, 2019, 60 (12) 1825-1832; DOI: https://doi.org/10.2967/jnumed.118.224568
You have access
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using ⁸⁹Zr-DFO-MSTP2109A Anti-STEAP1 Antibody
Jorge A. Carrasquillo, Bernard M. Fine, Neeta Pandit-Taskar, Steven M. Larson, Stephen E. Fleming, Josef J. Fox, Sarah M. Cheal, Joseph A. O’Donoghue, Shutian Ruan, Govind Ragupathi, Serge K. Lyashchenko, John L. Humm, Howard I. Scher, Mithat Gönen, Simon P. Williams, Daniel C. Danila and Michael J. Morris

Journal of Nuclear Medicine November 1, 2019, 60 (11) 1517-1523; DOI: https://doi.org/10.2967/jnumed.118.222844
You have access
Fully Automated ⁸⁹Zr Labeling and Purification of Antibodies
Alex J. Poot, Kevin W.A. Adamzek, Albert D. Windhorst, Maria J.W.D. Vosjan, Saskia Kropf, Hans-Jurgen Wester, Guus A.M.S. van Dongen and Danielle J. Vugts

Journal of Nuclear Medicine May 1, 2019, 60 (5) 691-695; DOI: https://doi.org/10.2967/jnumed.118.217158
Open Access
Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models
Thomas A. Burley, Chiara Da Pieve, Carlos D. Martins, Daniela M. Ciobota, Louis Allott, Wim J.G Oyen, Kevin J. Harrington, Graham Smith and Gabriela Kramer-Marek

Journal of Nuclear Medicine March 1, 2019, 60 (3) 353-361; DOI: https://doi.org/10.2967/jnumed.118.216069
You have access
An Overview of PET Radiochemistry, Part 2: Radiometals
Marie Brandt, Jens Cardinale, Margaret L. Aulsebrook, Gilles Gasser and Thomas L. Mindt

Journal of Nuclear Medicine October 1, 2018, 59 (10) 1500-1506; DOI: https://doi.org/10.2967/jnumed.117.190801
You have access
In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody–Drug Conjugates: Taking Advantage of Dual Labeling with ^195mPt and ⁸⁹Zr
Joey A. Muns, Veronica Montserrat, Hendrik-Jan Houthoff, Karlijn Codée-van der Schilden, Oene Zwaagstra, Niels J. Sijbrandi, Eugen Merkul and Guus A.M.S. van Dongen

Journal of Nuclear Medicine July 1, 2018, 59 (7) 1146-1151; DOI: https://doi.org/10.2967/jnumed.117.206672

Main menu

User menu

Search

89Zr

Pages